The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Why do we need to harmonize the use of MRD in MM?

During the 6th World Congress on Controversies in Multiple Myeloma (COMy) the Multiple Myeloma Hub spoke to Bruno Paiva, University of Navarra, Pamplona, ES, about the use of measurable residual disease (MRD) in MM. We asked, Why do we need to harmonize the use of MRD in MM?

Why do we need to harmonize the use of MRD in MM?

Bruno Paiva outlines the importance of MRD harmonization in MM. The harmonization will improve the quality and reproducibility of MRD results and ensure uniform reporting of MRD results. In addition, the high quality of MRD data will support the potential use of MRD as a surrogate biomarker, to accelerate drug development, in clinical trials.

Read a summary of the international harmonization for MRD assessment in clinical trials for patients with MM, here.

Share: